Edition:
India

Bioxcel Therapeutics Announces Bxcl501 Met Primary Endpoint In Phase 1B Placebo-Controlled Trial For Agitation In Patients With Schizophrenia


Monday, 22 Jul 2019 

July 22 (Reuters) - BioXcel Therapeutics Inc ::BIOXCEL THERAPEUTICS ANNOUNCES BXCL501 MET PRIMARY ENDPOINT IN PHASE 1B PLACEBO-CONTROLLED TRIAL IN THE TREATMENT OF AGITATION IN PATIENTS WITH SCHIZOPHRENIA.BIOXCEL THERAPEUTICS INC - WELL-TOLERATED WITH NO SERIOUS OR SEVERE ADVERSE EVENTS ACROSS ENTIRE DOSE RANGE.BIOXCEL THERAPEUTICS INC - BELIEVES RESULTS SUGGEST A PREDICTABLE AND DOSE-DEPENDENT RESPONSE FOR BXCL501.BIOXCEL THERAPEUTICS INC - BXCL501 WAS WELL-TOLERATED WITH NO SERIOUS OR SEVERE ADVERSE EVENTS ACROSS ENTIRE DOSE RANGE.BIOXCEL THERAPEUTICS INC - PLANS TO MEET WITH FDA TO OBTAIN ADDITIONAL FEEDBACK ON PROGRESSING TO A PHASE 3 PIVOTAL TRIAL. 

Company Quote

5.69
-0.11 -1.90%
8:47pm IST